Your browser doesn't support javascript.
loading
Sex-specific microglia state in the Neuroligin-4 knock-out mouse model of autism spectrum disorder.
Guneykaya, Dilansu; Ugursu, Bilge; Logiacco, Francesca; Popp, Oliver; Feiks, Maria Almut; Meyer, Niklas; Wendt, Stefan; Semtner, Marcus; Cherif, Fatma; Gauthier, Christian; Madore, Charlotte; Yin, Zhuoran; Çinar, Özcan; Arslan, Taner; Gerevich, Zoltan; Mertins, Philipp; Butovsky, Oleg; Kettenmann, Helmut; Wolf, Susanne A.
Affiliation
  • Guneykaya D; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Department of Neurobiology, Harvard Medical School, Boston, USA.
  • Ugursu B; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Germany; Psychoneuroimmunology, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germa
  • Logiacco F; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Popp O; Proteomics Platform, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute of Health, Berlin, Germany.
  • Feiks MA; Institute of Neurophysiology, Charité - Universitätsmedizin, Berlin, Germany.
  • Meyer N; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
  • Wendt S; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Semtner M; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Germany; Psychoneuroimmunology, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germa
  • Cherif F; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
  • Gauthier C; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Madore C; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Univ. Bordeaux, INRA, Bordeaux INP, NutriNeuro, Bordeaux, France.
  • Yin Z; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Çinar Ö; Molecular Immunotherapy, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute of Health, Berlin, Germany.
  • Arslan T; Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Solna, Sweden.
  • Gerevich Z; Institute of Neurophysiology, Charité - Universitätsmedizin, Berlin, Germany.
  • Mertins P; Proteomics Platform, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute of Health, Berlin, Germany.
  • Butovsky O; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Germany.
  • Kettenmann H; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • Wolf SA; Cellular Neuroscience, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany; Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Germany; Psychoneuroimmunology, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germa
Brain Behav Immun ; 111: 61-75, 2023 07.
Article de En | MEDLINE | ID: mdl-37001827
ABSTRACT
Neuroligin-4 (NLGN4) loss-of-function mutations are associated with monogenic heritable autism spectrum disorder (ASD) and cause alterations in both synaptic and behavioral phenotypes. Microglia, the resident CNS macrophages, are implicated in ASD development and progression. Here we studied the impact of NLGN4 loss in a mouse model, focusing on microglia phenotype and function in both male and female mice. NLGN4 depletion caused lower microglia density, less ramified morphology, reduced response to injury and purinergic signaling specifically in the hippocampal CA3 region predominantly in male mice. Proteomic analysis revealed disrupted energy metabolism in male microglia and provided further evidence for sexual dimorphism in the ASD associated microglial phenotype. In addition, we observed impaired gamma oscillations in a sex-dependent manner. Lastly, estradiol application in male NLGN4-/- mice restored the altered microglial phenotype and function. Together, these results indicate that loss of NLGN4 affects not only neuronal network activity, but also changes the microglia state in a sex-dependent manner that could be targeted by estradiol treatment.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble du spectre autistique Limites: Animals Langue: En Journal: Brain Behav Immun Sujet du journal: ALERGIA E IMUNOLOGIA / CEREBRO / PSICOFISIOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble du spectre autistique Limites: Animals Langue: En Journal: Brain Behav Immun Sujet du journal: ALERGIA E IMUNOLOGIA / CEREBRO / PSICOFISIOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique